{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:45:29Z","timestamp":1767991529533,"version":"3.49.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1097\/md.0000000000006306","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T12:36:47Z","timestamp":1489581407000},"page":"e6306","source":"Crossref","is-referenced-by-count":12,"title":["UGT1A1*28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients"],"prefix":"10.1097","volume":"96","author":[{"given":"Marcelo Moreira Tavares","family":"de Souza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Van","family":"Vaisberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Martins","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline Siqueira","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"daSilvaFerreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Dominguez","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena Scavone","family":"Paschoale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flair Jos\u00e9","family":"Carrilho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzane Kioko","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20-20210309","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-8278(02)00359-8","article-title":"Inherited disorders of bilirubin metabolism","volume":"38","author":"Bosma","year":"2003","journal-title":"J Hepatol"},{"key":"R2-20-20210309","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","article-title":"The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome","volume":"333","author":"Bosma","year":"1995","journal-title":"N Engl J Med"},{"key":"R3-20-20210309","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(96)91273-8","article-title":"Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome","volume":"347","author":"Monaghan","year":"1996","journal-title":"Lancet"},{"key":"R4-20-20210309","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","article-title":"Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan","volume":"22","author":"Innocenti","year":"2004","journal-title":"J Clin Oncol"},{"key":"R5-20-20210309","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/cncr.23370","article-title":"UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma","volume":"112","author":"Liu","year":"2008","journal-title":"Cancer"},{"key":"R6-20-20210309","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.2147\/OTT.S95149","article-title":"The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer","volume":"8","author":"Xiao","year":"2015","journal-title":"Onco Targets Ther"},{"key":"R7-20-20210309","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00280-016-3057-z","article-title":"UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer","volume":"78","author":"Xu","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"R8-20-20210309","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1023\/A:1008438109725","article-title":"UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan","volume":"9","author":"Ando","year":"1998","journal-title":"Ann Oncol"},{"key":"R9-20-20210309","first-page":"950","article-title":"Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans","volume":"60","author":"Guillemette","year":"2000","journal-title":"Cancer Res"},{"key":"R10-20-20210309","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cancergen.2012.01.015","article-title":"Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer","volume":"205","author":"Bajro","year":"2012","journal-title":"Cancer Genet"},{"key":"R11-20-20210309","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/hep.20770","article-title":"UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver","volume":"42","author":"Girard","year":"2005","journal-title":"Hepatology"},{"key":"R12-20-20210309","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10409239109081125","article-title":"Roles of UDP-glucuronosyltransferases in chemical carcinogenesis","volume":"26","author":"Bock","year":"1991","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"R13-20-20210309","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.mehy.2011.03.047","article-title":"Is Gilbert syndrome a new risk factor for breast cancer?","volume":"77","author":"Astolfi","year":"2011","journal-title":"Med Hypotheses"},{"key":"R14-20-20210309","first-page":"15","article-title":"Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan Genet M","volume":"11","year":"2009","journal-title":"ed"},{"key":"R15-20-20210309","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1665-2681(19)31774-0","article-title":"Gilbert's syndrome and antiviral therapy of hepatitis C","volume":"8","author":"Deterding","year":"2009","journal-title":"Ann Hepatol"},{"key":"R16-20-20210309","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0016-5085(76)80151-5","article-title":"Abnormal hepatic transport of indocyanine green in Gilbert's syndrome","volume":"70","author":"Martin","year":"1976","journal-title":"Gastroenterology"},{"key":"R17-20-20210309","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003088-197904030-00004","article-title":"Gilbert's syndrome and drug metabolism","volume":"4","author":"Macklon","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"R18-20-20210309","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/j.1572-0241.2005.41857.x","article-title":"UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age","volume":"100","author":"Tseng","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R19-20-20210309","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"R21-20-20210309","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","article-title":"Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?","volume":"95","author":"Beutler","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R22-20-20210309","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1079-9796(03)00071-8","article-title":"The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications","volume":"31","author":"Premawardhena","year":"2003","journal-title":"Blood Cells Mol Dis"},{"key":"R23-20-20210309","first-page":"106","article-title":"(TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome","volume":"84","author":"Iolascon","year":"1999","journal-title":"Haematologica"},{"key":"R24-20-20210309","first-page":"319","article-title":"A Caucasian boy with Gilbert's syndrome heterozygous for the (TA)(8) allele","volume":"85","author":"Tsezou","year":"2000","journal-title":"Haematologica"},{"key":"R25-20-20210309","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bcmd.2005.09.002","article-title":"Analysis of the UDP-glucuronosyltransferase gene in Portuguese patients with a clinical diagnosis of Gilbert and Crigler\u2013Najjar syndromes","volume":"36","author":"Costa","year":"2006","journal-title":"Blood Cells Mol Dis"},{"key":"R26-20-20210309","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ajmg.10209","article-title":"Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil","volume":"108","author":"Fertrin","year":"2002","journal-title":"Am J Med Genet"},{"key":"R27-20-20210309","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.106.633206","article-title":"Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study","volume":"114","author":"Lin","year":"2006","journal-title":"Circulation"},{"key":"R28-20-20210309","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.atherosclerosis.2009.02.039","article-title":"Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene for anti-atherogenic serum bilirubin levels\u2014the Framingham Heart Study","volume":"206","author":"Lin","year":"2009","journal-title":"Atherosclerosis"},{"key":"R29-20-20210309","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cpt.269","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing","volume":"99","author":"Gammal","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"R30-20-20210309","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na\u00efve patients with chronic hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"key":"R31-20-20210309","doi-asserted-by":"crossref","first-page":"e54279","DOI":"10.1371\/journal.pone.0054279","article-title":"52-Week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B","volume":"8","author":"Piratvisuth","year":"2013","journal-title":"PLoS One"},{"key":"R32-20-20210309","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1124\/mol.104.007146","article-title":"Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene","volume":"67","author":"Lankisch","year":"2005","journal-title":"Mol Pharmacol"},{"key":"R33-20-20210309","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2217\/pgs-2016-0063","article-title":"Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity","volume":"17","author":"Bins","year":"2016","journal-title":"Pharmacogenomics"},{"key":"R34-20-20210309","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jcph.625","article-title":"Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer","volume":"56","author":"Goey","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"R35-20-20210309","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2133\/dmpk.DMPK-14-RG-031","article-title":"Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia","volume":"29","author":"Abumiya","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"R36-20-20210309","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1345\/aph.1R550","article-title":"Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review","volume":"47","author":"Culley","year":"2013","journal-title":"Ann Pharmacother"},{"key":"R37-20-20210309","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00280-010-1445-3","article-title":"The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1","volume":"67","author":"Fujita","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"R38-20-20210309","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/infdis\/jiq043","article-title":"Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study","volume":"203","author":"Lubomirov","year":"2011","journal-title":"J Infect Dis"},{"key":"R39-20-20210309","doi-asserted-by":"crossref","first-page":"ofv085","DOI":"10.1093\/ofid\/ofv085","article-title":"Screening for UGT1A1 genotype in study A5257 would have markedly reduced premature discontinuation of atazanavir for hyperbilirubinemia","volume":"2","author":"Vardhanabhuti","year":"2015","journal-title":"Open Forum Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000006306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:45:16Z","timestamp":1620960316000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201703170-00020"}},"subtitle":["Outcomes from a case\u2013control study"],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000006306","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}